Skip to main content

Advertisement

Log in

Big data opens a window onto wellness

  • News & Views
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Longitudinal multi-omics data, clinical tests and biomarker analyses across a large cohort lay the groundwork for understanding the transition from wellness to disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: An individual undergoes multi-modality molecular testing.

References

  1. Wilson, P.W. et al. Circulation 97, 1837–1847 (1998).

    Article  CAS  Google Scholar 

  2. Price, N.D. et al. Nat. Biotechnol. 35, 747–756 (2017).

    Article  CAS  Google Scholar 

  3. Sheridan, C. Nat. Biotechnol. 33, 887–889 (2015).

    Article  CAS  Google Scholar 

  4. Li, X. et al. PLoS Biol. 15, e2001402 (2017).

    Article  Google Scholar 

  5. Telenti, A. et al. Proc. Natl. Acad. Sci. USA 113, 11901–11906 (2016).

    Article  CAS  Google Scholar 

  6. Dewey, F.E. et al. Science 354, aaf6814 (2016).

    Article  Google Scholar 

  7. Sudlow, C. et al. PLoS Med. 12, e1001779 (2015).

    Article  Google Scholar 

  8. Morgan, A.A., Chen, R. & Butte, A.J. Genome Med. 2, 30 (2010).

    Article  Google Scholar 

  9. Butte, A.J. Proc. Natl. Acad. Sci. USA 113, 12344–12346 (2016).

    Article  CAS  Google Scholar 

  10. Kasahara, A.K., Singh, R.J. & Noymer, A. PLoS One 8, e65785 (2013).

    Article  CAS  Google Scholar 

  11. Taylor, N.P. Fierce Biotech http://www.fiercebiotech.com/genomics/venter-s-human-longevity-starts-50-000-health-testing-service (2015).

Download references

Acknowledgements

A.J.B. is supported by the National Institutes of Health under award number 1OT2OD024611. The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Atul J Butte.

Ethics declarations

Competing interests

A.J.B. has a minor investment in Illumina and other biotech companies. He is a cofounder and consultant to Personalis, a company offering services in medical genome sequencing. A.J.B. is a scientific advisor to Geisinger Health System, Helix, and uBiome. In the recent past, he has been a consultant to Regeneron, 10x Genomes, Verinata and Pathway Genomics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Butte, A. Big data opens a window onto wellness. Nat Biotechnol 35, 720–721 (2017). https://doi.org/10.1038/nbt.3934

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3934

  • Springer Nature America, Inc.

This article is cited by

Navigation